Related Experiment Video
Updated: Jan 3, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
711
Maintenance Treatment for Patients With Mantle Cell Lymphoma: A Systematic Review and Meta-analysis of Randomized
Liat Vidal1, Anat Gafter-Gvili1,2,3, Martin Dreyling4
1Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.
Hemasphere
|November 15, 2019
Summary
Rituximab maintenance therapy improves progression-free survival for mantle cell lymphoma (MCL) patients but increases neutropenia risk. Current treatments for MCL are insufficient, highlighting the need for effective maintenance strategies.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Mantle cell lymphoma (MCL) treatment remains challenging, with current therapies often insufficient for cure.
- There is a need to evaluate the role of maintenance therapy in improving outcomes for MCL patients.
Purpose of the Study:
- To systematically review and meta-analyze randomized controlled trials assessing the efficacy and safety of maintenance therapy in MCL.
- To determine the impact of rituximab maintenance on survival and adverse events in MCL.
Main Methods:
- A systematic review and meta-analysis of six randomized controlled trials involving 858 MCL patients.
- Pooled analysis of hazard ratios (HR) for overall survival and progression-free survival (PFS), and risk ratios (RR) for adverse events.
Main Results:
- Rituximab maintenance showed a trend towards improved overall survival (HR 0.79) and significantly improved PFS (HR 0.58).
- Increased risk of neutropenia was observed with rituximab maintenance (RR 1.31), but grade 3-4 infection rates were similar between groups.
- Quality of life outcomes were not reported in the included trials.
Conclusions:
- Rituximab maintenance is recommended following R-CHOP or R-cytarabine induction in the frontline and R-CHOP in the relapse setting for MCL.
- The benefit of maintenance after other induction regimens (e.g., bendamustine, fludarabine) requires further investigation.
- Long-term data on other maintenance strategies for MCL are still pending.
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K